Mycobacterium Tuberculosis

News Mycobacterium Tuberculosis

• Data from historic phase IIb clinical trial for tuberculosis vaccine candidate MVA85A

  Data from a Phase IIb clinical trial evaluating the safety and efficacy of MVA85A in preventing tuberculosis (TB) in infants. MVA85A is a TB vaccine candidate designed to boost immune responses already primed by the Bacille Calmette-Guérin (BCG) vaccine, the currently licensed and widely used TB vac more

• Scientists reveal how natural antibiotic kills tuberculosis bacterium

  A natural product secreted by a soil bacterium shows promise as a new drug to treat tuberculosis report scientists in a new study published in EMBO Molecular Medicine. A team of scientists working in Switzerland has shown how pyridomycin, a natural antibiotic produced by the bacterium Dactylosporang more

• NUS partners FIND to discover novel biomarkers for Tuberculosis detection

  A research team from the National University of Singapore (NUS) Singapore Lipidomics Incubator (SLING) is collaborating with the Foundation for Innovative New Diagnostics (FIND) to identify novel target molecules to be employed as biomarkers for the detection of active tuberculosis (TB). The aim is more

Publications Mycobacterium Tuberculosis

• Evidence for Diversifying Selection in a Set of Mycobacterium tuberculosis Genes in Response to Antibiotic- and Nonantibiotic-Related Pressure

  Tuberculosis (TB) is a global health problem estimated to kill 1.4 million people per year. Recent advances in the genomics of the causative agents of TB, bacteria known as the Mycobacterium tuberculosis complex (MTBC), have allowed a better comprehension of its population structure and provided th more

• The re‐emergence of tuberculosis: what have we learnt from molecular epidemiology

  Summary Tuberculosis (TB) has re‐emerged over the past two decades: in industrialised countries in association with immigration and in Africa due to the HIV epidemic. Drug‐resistant tuberculosis is a major threat worldwide. The variable and uncertain impact of TB control necessitates not only be more

• Proteases in Mycobacterium tuberculosis pathogenesis: potential as drug targets

  TB is still a major global health problem causing over 1 million deaths per year. An increasing problem of drug resistance in the causative agent, Mycobacterium tuberculosis, as well as problems with the current lengthy and complex treatment regimens, lends urgency to the need to develop new antitub more

Market studies Mycobacterium Tuberculosis

• Mycobacterium Tuberculosis Infections – Pipeline Review, H2 2012

  Introduction Global Markets Direct’s, 'Mycobacterium Tuberculosis Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Mycobacterium Tuberculosis Infections, complete with latest u more

• Artec, Inc. - Strategic SWOT Analysis Review

  Artec, Inc. (Artec) is a publicly held pharmaceutical company. It is principally engaged in the manufacture and distribution of a polysaccharide compound, Tubercin, which is used in the treatment of various cancers. Tubercin is a mixture of low molecular weight immune system stimulant derived from a more

• Artec, Inc. (ATKJ) - Strategic SWOT Analysis Review

  Artec, Inc. (Artec) is a publicly held pharmaceutical company. It is principally engaged in the manufacture and distribution of a polysaccharide compound, Tubercin, which is used in the treatment of various cancers. Tubercin is a mixture of low molecular weight immune system stimulant derived from a more

Websites Mycobacterium Tuberculosis